Program
retatrutide
Also written as “Retatrutide”, “LY3437943” and “Retatrutide (LY3437943)”.
Its studies are mostly in Obesity · Diabetes Mellitus, Type 2 · Atherosclerosis · Non-alcoholic Fatty Liver Disease · Diabetes Mellitus, led by 2 companies.
Drug pageRetatrutide: every studyAll 33 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Eli Lillyits history only | 3210 open or running | phase 3since May 22, 2023 | Feb 13, 2019 | Nov 2026phase 3 · NCT06662383 |
| Hudson Biotechits history only | 11 open or running | phase 2since Mar 8, 2026 | Mar 8, 2026 | Mar 14, 2027phase 2 · NCT07467447 |
- Named in Eli Lilly’s own pipeline as
Retatrutide
, phase 3, as of Oct 29, 2026 (source).
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Not listed one by one: 17 earlier studies, Feb 13, 2019 to Aug 16, 2023.
- Jan 19, 2023Named retatrutideINNProposed as its International Nonproprietary Name in WHO's List 128 · before, LY3437943
- Sep 11, 2023Phase 1 study in OverweightEli Lilly · NCT06039826 · 46 enrolled · United States
- Feb 8, 2024Phase 3 study in Diabetes Mellitus, Type 2Eli Lilly · NCT06260722 · 1,250 enrolled · United States, Argentina, Canada and more
- Mar 1, 2024Phase 3 study in Diabetes Mellitus, Type 2Eli Lilly · NCT06297603 · 341 enrolled · United States, Argentina, Brazil and more
- Mar 11, 2024Phase 1 study in ObesityEli Lilly · NCT06313528 · 85 enrolled · United States
- Apr 3, 20242 phase 3 studiesEli Lilly · NCT06354660, NCT06383390
- Oct 25, 2024Phase 3 study in ObesityEli Lilly · NCT06662383 · 800 enrolled · United States, Argentina, Germany and more
- Jan 31, 2025Phase 1 study in HealthyEli Lilly · NCT06808802 · 30 enrolled · Singapore
- Feb 28, 2025Phase 3 study in ObesityEli Lilly · NCT06859268 · 643 enrolled · United States, Canada, United Kingdom
- May 14, 20252 phase 1 studiesEli Lilly · NCT06982859, NCT06982846
- May 28, 2025Phase 3 study in ObesityEli Lilly · NCT07035093 · 586 enrolled · United States, Argentina, Canada and more
- Aug 28, 2025Phase 3 study in Non-alcoholic Fatty Liver DiseaseEli Lilly · NCT07165028 · 4,500 planned · United States, Argentina, Australia and more
- Nov 14, 2025Phase 3 study in ObesityEli Lilly · NCT07232719 · 250 enrolled · United States, United Kingdom
- Jan 16, 2026Phase 3 study in ObesityEli Lilly · NCT07357415 · 600 enrolled · United States, Argentina, Canada
- Mar 8, 2026Hudson Biotech’s first study: phase 2 study in ObesityNew to Hudson BiotechHudson Biotech · NCT07467447 · 300 planned · China
Ahead
- Nov 2026Primary completion: phase 3 study in ObesityEli Lilly · NCT06662383
- Jan 2027Primary completion: phase 1 study in Diabetes MellitusEli Lilly · NCT06982859
- Mar 14, 2027Primary completion: phase 2 study in ObesityHudson Biotech · NCT07467447
- Jun 2027Primary completion: phase 3 study in ObesityEli Lilly · NCT07232719
TargetBeta
“Glucagon receptor agonist; Glucagon-like peptide 1 receptor agonist; Gastric inhibitory polypeptide receptor agonist”ChEMBL 37, by rule
Other programs on the same three targets
Studies
All 33 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07467447Obesity · China | 2 | Recruiting | Hudson Biotech | Mar 14, 2027 | 300 |
| NCT07357415Obesity · United States, Argentina, Canada | 3 | Active, not recruiting | Eli Lilly | Oct 2028 | 600 |
| NCT07232719Obesity · United States, United Kingdom | 3 | Active, not recruiting | Eli Lilly | Jun 2027 | 250 |
| NCT07165028Non-alcoholic Fatty Liver Disease · United States, Argentina, Australia and more | 3 | Recruiting | Eli Lilly | Aug 2030 | 4,500 |
| NCT07035093Obesity · United States, Argentina, Canada and more | 3 | Active, not recruiting | Eli Lilly | Sep 2027 | 586 |
| NCT06982859Diabetes Mellitus · Germany | 1 | Active, not recruiting | Eli Lilly | Jan 2027 | 95 |
| NCT06982846Diabetes Mellitus, Type 2 · Austria | 1 | Completed | Eli Lilly | May 4, 2026 | 80 |
| NCT06859268Obesity · United States, Canada, United Kingdom | 3 | Active, not recruiting | Eli Lilly | Apr 2028 | 643 |
| NCT06808802Healthy · Singapore | 1 | Completed | Eli Lilly | Apr 15, 2025 | 30 |
| NCT06662383Obesity · United States, Argentina, Germany and more | 3 | Active, not recruiting | Eli Lilly | Nov 2026 | 800 |
| NCT06383390Atherosclerosis · United States, Argentina, Australia and more | 3 | Active, not recruiting | Eli Lilly | Feb 2029 | 10,000 |
| NCT06354660Diabetes Mellitus, Type 2 · United States, India, Mexico and more | 3 | Completed | Eli Lilly | Jan 22, 2026 | 537 |
| NCT06313528Obesity · United States | 1 | Completed | Eli Lilly | Aug 26, 2025 | 85 |
| NCT06297603Diabetes Mellitus, Type 2 · United States, Argentina, Brazil and more | 3 | Active, not recruiting | Eli Lilly | Oct 26, 2026 | 341 |
| NCT06260722Diabetes Mellitus, Type 2 · United States, Argentina, Canada and more | 3 | Active, not recruiting | Eli Lilly | Aug 27, 2026 | 1,250 |
| NCT06039826Overweight · United States | 1 | Completed | Eli Lilly | Jul 11, 2024 | 46 |
| NCT06003465Healthy · United States | 1 | Completed | Eli Lilly | Feb 8, 2024 | 57 |
| NCT05959096Healthy · United States | 1 | Completed | Eli Lilly | Jul 25, 2024 | 85 |
| NCT05936151Overweight · United States, Canada, Italy and more | 2 | Completed | Eli Lilly | Oct 1, 2025 | 146 |
| NCT05931367Obesity · United States, Australia, Canada and more | 3 | Completed | Eli Lilly | Nov 14, 2025 | 445 |
| NCT05929079Diabetes Mellitus, Type 2 · United States, Argentina, Australia and more | 3 | Completed | Eli Lilly | Jun 16, 2026 | 1,152 |
| NCT05929066Obesity · United States, Australia, Brazil and more | 3 | Completed | Eli Lilly | Apr 6, 2026 | 2,335 |
| NCT05916560Hepatic Insufficiency · United States | 1 | Completed | Eli Lilly | Mar 2, 2025 | 43 |
| NCT05882045Obesity · United States, Argentina, Australia and more | 3 | Completed | Eli Lilly | Apr 16, 2026 | 1,946 |
| NCT05757531Healthy · United States | 1 | Completed | Eli Lilly | Jun 23, 2023 | 7 |
| NCT05611957Renal Insufficiency · United States | 1 | Completed | Eli Lilly | Sep 5, 2023 | 29 |
| NCT05548231Overweight · China | 1 | Completed | Eli Lilly | Jul 27, 2023 | 32 |
| NCT05445232Obesity · United States | 1 | Completed | Eli Lilly | Feb 24, 2023 | 32 |
| NCT04881760Obesity · United States, Puerto Rico | 2 | Completed | Eli Lilly | May 16, 2022 | 338 |
| NCT04867785Diabetes Mellitus, Type 2 · United States, Puerto Rico | 2 | Completed | Eli Lilly | Jul 8, 2022 | 281 |
| NCT04823208Diabetes Mellitus, Type 2 · Japan | 1 | Completed | Eli Lilly | Jun 23, 2022 | 64 |
| NCT04143802Diabetes Mellitus, Type 2 · United States | 1 | Completed | Eli Lilly | Dec 28, 2020 | 72 |
| NCT03841630Healthy · Singapore | 1 | Completed | Eli Lilly | Jul 25, 2019 | 45 |
How it is read
Names in the registry
- “Retatrutide”, 18 entries
- “LY3437943”, 14 entries
- “Retatrutide (LY3437943)”, 1 entry
- “[¹⁴C]-LY3437943”, 1 entry
Conditions, from the studies’ own filings
- Obesity, 14 studies
- Diabetes Mellitus, Type 2, 8 studies
- Atherosclerosis, 1 study
- Non-alcoholic Fatty Liver Disease, 1 study
- Diabetes Mellitus, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.